{"id":"NCT01585155","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis","officialTitle":"Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Ulcerative Colitis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2014-09","completion":"2014-09","firstPosted":"2012-04-25","resultsPosted":"2019-10-21","lastUpdate":"2019-11-05"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pediatric Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"TA-650","otherNames":[]}],"arms":[{"label":"TA-650","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the the efficacy of TA-650 using Clinical activity index (CAI) score and other evaluation indicators in pediatric patients with moderate to severe ulcerative colitis after TA-650 administration of at a dose of 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks at weeks 14 and 22. The safety and pharmacokinetics are also evaluated.","primaryOutcome":{"measure":"Percent of Patients Who Achieved CAI Remission","timeFrame":"Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30","effectByArm":[{"arm":"TA-650","deltaMin":60,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["31607268"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":21},"commonTop":["Double stranded DNA antibody positive","Nasopharyngitis","Enteritis infectious","Upper respiratory tract infection","Iron deficiency anaemia"]}}